Neonc Technologies’ (NTHI) Buy Rating Reaffirmed at BTIG Research

Neonc Technologies (NASDAQ:NTHI)‘s stock had its “buy” rating reaffirmed by research analysts at BTIG Research in a report released on Tuesday,Benzinga reports. They currently have a $15.00 price objective on the stock. BTIG Research’s price objective indicates a potential upside of 180.90% from the stock’s current price.

NTHI has been the topic of several other research reports. Maxim Group began coverage on shares of Neonc Technologies in a research note on Monday, May 18th. They issued a “buy” rating and a $20.00 price objective on the stock. Weiss Ratings upgraded shares of Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Finally, Alliance Global Partners began coverage on shares of Neonc Technologies in a research note on Tuesday, May 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $16.00.

Neonc Technologies Stock Performance

Shares of NTHI stock opened at $5.34 on Tuesday. Neonc Technologies has a 12 month low of $3.20 and a 12 month high of $12.99. The business’s 50 day moving average is $5.94 and its two-hundred day moving average is $7.99.

Neonc Technologies (NASDAQ:NTHI) last announced its quarterly earnings results on Monday, May 18th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.16).

Insider Buying and Selling

In other news, President Amir F. Heshmatpour bought 20,000 shares of Neonc Technologies stock in a transaction that occurred on Thursday, April 2nd. The stock was purchased at an average cost of $6.09 per share, with a total value of $121,800.00. Following the completion of the transaction, the president directly owned 3,012,000 shares in the company, valued at $18,343,080. This trade represents a 0.67% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired 80,700 shares of company stock valued at $423,590 over the last three months.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NTHI. Royal Bank of Canada bought a new position in Neonc Technologies in the first quarter worth $247,000. Bank of America Corp DE bought a new position in shares of Neonc Technologies during the second quarter valued at $801,000. Foundations Investment Advisors LLC bought a new position in shares of Neonc Technologies during the third quarter valued at $100,000. HighPoint Advisor Group LLC lifted its holdings in shares of Neonc Technologies by 424.8% during the third quarter. HighPoint Advisor Group LLC now owns 950,232 shares of the company’s stock valued at $8,628,000 after acquiring an additional 769,163 shares during the period. Finally, Vanguard Group Inc. bought a new position in shares of Neonc Technologies during the third quarter valued at $1,279,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.